Drug Profile

Research programme: selective peptide MC4R agonists - Palatin Technologies

Alternative Names: MCR4 agonist therapeutic - Palatin Technologies; Melanocortin 4 receptor agonists - Palatin Technologies

Latest Information Update: 27 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 May 2026 Palatin Technologies announces intention to submit an IND application for Obesity, in the fourth quarter of 2026
06 Nov 2025 Palatin Technologies plans a phase I SAD/MAD trial trial for Obesity in the mid 2026
25 Jul 2024 Preclinical trials in Obesity in USA (SC), prior to July 2024 (Palatin Technologies pipeline, July 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com